Ashland schedules November 4 results: Ashland stock gains 2.40 percent

Published on 10/20/2026 at 19:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal third-quarter sales rose 7.00 percent to USD 497.00 million. Ashland stock costs EUR 64.00 on October 20, 2026, up 2.40 percent versus the Frankfurt close.

Reporting date and market position

Ashland's next earnings date is November 4, 2026.
Fiscal third-quarter sales rose 7.00 percent to USD 497.00 million.
Ashland stock costs EUR 64.00 at Lang & Schwarz on October 20, 2026 at 7:35 p.m. CEST, 2.40 percent above the Frankfurt close of October 19, 2026.
Ashland paid a quarterly dividend of USD 0.42 on September 15, 2026.

ASH, US0441861046, Illustration mit AI erstellt.

Ashland (ISIN US0441861046) has its next earnings date set for November 4, 2026, according to Simply Wall St. Fiscal third-quarter sales rose 7.00 percent year over year to USD 497.00 million, while adjusted earnings per share reached USD 1.02, according to Yahoo Finance. Ashland was trading at EUR 64.00 at Lang & Schwarz on October 20, 2026 at 7:35 p.m. CEST, up 2.40 percent versus the Frankfurt close of October 19, 2026 at EUR 62.50.

Sales growth meets margin pressure

The third-quarter sales increase was paired with uneven operating performance. Life Sciences sales rose 11.00 percent year over year to USD 180.00 million, while adjusted EBITDA increased 11.00 percent to USD 60.00 million and produced a 33.00 percent margin, Yahoo Finance reported on September 25, 2026.

Stock remains below its yearly high

On the NYSE, Ashland was trading at USD 71.86 on October 20, 2026 at 1:40 p.m. EDT. The same quote placed the 52-week range at USD 47.12 to USD 78.25 and market capitalization at USD 3.3 billion. The current NYSE price stood 8.17 percent below the 52-week high, calculated from USD 71.86 and USD 78.25.

Valuation and the next date

Ashland's price-to-earnings ratio was 63.64 on October 20, 2026. The company paid a quarterly dividend of USD 0.42 on September 15, 2026, equivalent to a 2.40 percent yield, according to MarketBeat. Ashland's investor-relations page also lists the October 8, 2026 commercialization of Forzango biofunctional for sports-minded consumers, according to Ashland.

Comparison with peers

Ashland (NYSE, USD): up 2.40 percent versus the Frankfurt close on October 20, 2026, price-to-earnings ratio 63.64, market capitalization USD 3.3 billion.

Dow (NYSE, USD): up 0.58 percent on October 20, 2026, price-to-earnings ratio minus 16.64, market capitalization USD 21.9 billion.

DuPont de Nemours (NYSE, USD): up 2.03 percent on October 20, 2026, price-to-earnings ratio 292.82, market capitalization USD 17.8 billion.

What the November date adds

The November 4 reporting date gives investors the next fixed point for testing whether the USD 497.00 million sales base and USD 109.00 million adjusted EBITDA can improve. The contrast is clear: Life Sciences delivered USD 60.00 million of adjusted EBITDA in the fiscal third quarter, while companywide adjusted EBITDA fell 4.00 percent year over year.

Trading level after the Xetra session

Ashland's euro quotation stood 2.40 percent above the Frankfurt close of October 19, 2026, with the NYSE quote at USD 71.86 on October 20, 2026. The stock was 8.17 percent below its USD 78.25 52-week high.

The further course of trading is shown by the continuously updated real-time quote of Ashland stock.